IgE antibodies to recombinant core antigens ando non-structural proteins NS3, NS4A/B e NS5B of the hepatitis C vírus.
Hepatitis C, IgE, recombinant antigens, cytokines
In hepatitis C, HCV persistence may cause cirrhosis, liver failure and hepatocellular carcinoma. New biomarkers and the development of efficient screening tests are still necessary to diagnose seronegative anti-HCV IgG patients. Aim: The aim of this study was to investigate the adaptive immune response of anti-HCV IgE antibodies in patients chronically infected with HCV, and to test its use as a biomarker of antiviral treatment. Methods and Results: Twenty patients before and after 12 weeks of antiviral treatment with interferon-α / ribavirin took part of this study. Amplified indirect ELISAs tested IgE antibodies to recombinant antigens from core and from nonstructural proteins NS3, NS4A/B and NS5B with IgG-depleted sera. Immunocytometric assays determined serum levels of cytokines (TNF-α. IFN-γ, IL-4, IL-6 and IL-10). IgE antibodies to the HCV-recombinant antigens were detected in the hepatitis C patients. Except for NS5B IgE antibodies, there was a significant drop in the levels of IgE to Core, NS4A/B and mainly NS3 after 12 weeks of antiviral therapy regardless of the presence of an early sustained virologic response. Conclusions: These results suggest that IgE antibodies to core and non-structural proteins actively participate in the adaptive immune response to HCV infection and that anti-NS3 IgE should be investigated as a biomarker to monitor antiviral therapy and to exclude hepatitis C in anti-HCV IgG seronegative patients.